1)Mangione CM, Lee PP, Pitts J:Psychometric properties of the National Eye Institute Visual Function Questionnaire(NEI-VFQ). Arch Ophthalmol 116:1496-1504, 1998
2)Mangione CM, Lee PP, Gutierrez PR:Development of the 25-Item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119:1050-1058, 2001
3)Brody BL, Gamst AC, Williams RA:Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 108:1893-1900, 2001
4)Orr P, Rentz AM, Margolis MK:Validation of the National Eye Institute Visual Function Questionnaire-25(NEI VFQ-25)in age-related macular degeneration. Invest Ophthalmol Vis Sci 52:3354-3359, 2011
5)Yuzawa M, Fujita K, Tanaka E:Assessing quality of life in the treatment of patients with age-related macular degenerateon:clinical research findings and recommendations for clinical practice. Clin Ophthalmol 7:1325-1332, 2013
6)Suzukamo Y, Oshika T, Yuzawa M:Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire(NEI VFQ-25), Japanese version:Health Qual life Outcomes 3:65, 2005
7)Yuzawa M, Fujita K, Wittrup-Jensen KU:Improvement in vision-related function with intravitreal aflibercept:data from phase 3 studies in wet age-related macular degeneration. Ophthalmology 122:571-578, 2015
8)Yamamoto A, Okada AA, Kano M:One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122:1866-1872, 2015